Biodesix Q1 revenue $14.8M (+64% YoY); 79% gross margin; raises $55M

BIODESIX INC

2024-Q1 EPS reported -$0.14 revenue$14,818,000

Total revenue $14.8M (+64% YoY); Lung Diagnostic revenue $13.8M (+60%) on 11,900 test volume (+57%).
Gross margin 79% vs 65% YoY; net loss improved 27% to $13.6M.
Adjusted EBITDA loss $7.0M, improvement of 48% from $13.4M loss in Q1 2023.
Raised $55M gross proceeds in April 2024 oversubscribed offering; cash $11.5M at Q1 end excluding proceeds.
Reaffirmed 2024 revenue guidance of $65M-$68M; new collaboration with MSKCC for cancer diagnostics.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BIODESIX INC reported the first quarter ended March 31, 2024 results: revenue $14.8 million, net income $13.6 million. Guidance reaffirmed.

Period: the first quarter ended March 31, 2024
Revenue: $14.8 million
Net income: $13.6 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Total revenue of $14.8 million, an increase of 64%

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

BIODESIX INC filing history →

Source: SEC EDGAR

accession 0000950170-24-055608

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.